JP2022510313A5 - - Google Patents
Info
- Publication number
- JP2022510313A5 JP2022510313A5 JP2021531100A JP2021531100A JP2022510313A5 JP 2022510313 A5 JP2022510313 A5 JP 2022510313A5 JP 2021531100 A JP2021531100 A JP 2021531100A JP 2021531100 A JP2021531100 A JP 2021531100A JP 2022510313 A5 JP2022510313 A5 JP 2022510313A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- compound according
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774482P | 2018-12-03 | 2018-12-03 | |
| US62/774,482 | 2018-12-03 | ||
| US201962938410P | 2019-11-21 | 2019-11-21 | |
| US62/938,410 | 2019-11-21 | ||
| PCT/US2019/064169 WO2020117759A1 (en) | 2018-12-03 | 2019-12-03 | Small molecule degraders of helios and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510313A JP2022510313A (ja) | 2022-01-26 |
| JP2022510313A5 true JP2022510313A5 (enExample) | 2022-12-08 |
| JP7709378B2 JP7709378B2 (ja) | 2025-07-16 |
Family
ID=70974869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531100A Active JP7709378B2 (ja) | 2018-12-03 | 2019-12-03 | Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12227488B2 (enExample) |
| EP (1) | EP3890736A4 (enExample) |
| JP (1) | JP7709378B2 (enExample) |
| KR (1) | KR102972506B1 (enExample) |
| CN (1) | CN113490495B (enExample) |
| AU (1) | AU2019391016B2 (enExample) |
| CA (1) | CA3119526A1 (enExample) |
| WO (1) | WO2020117759A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230192644A1 (en) * | 2020-05-21 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Piperidine-2,6-diones as small molecule degraders of helios and methods of use |
| EP4168007A1 (en) * | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| IL301690A (en) * | 2020-10-16 | 2023-05-01 | Dana Farber Cancer Inst Inc | Piperidinyl small molecule degraders of helios and methods of use |
| CN116669769A (zh) * | 2020-10-16 | 2023-08-29 | 达纳－法伯癌症研究所公司 | Helios的哌啶基小分子降解剂和使用方法 |
| CN113046391A (zh) * | 2021-03-22 | 2021-06-29 | 上海科技大学 | 一种crbn基因人源化动物肿瘤细胞模型的构建方法和用途 |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026026826A1 (en) * | 2024-07-31 | 2026-02-05 | Insilico Medicine Ip Limited | Crbn-binding compounds and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2026080794A1 (en) * | 2024-10-11 | 2026-04-16 | Bristol-Myers Squibb Company | Chemical compounds useful for degrading proteins |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026102277A1 (en) * | 2024-11-08 | 2026-05-15 | Plexium, Inc. | Combination therapies comprising ikzf2 degrader compounds |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143283B1 (en) * | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
| JP4361273B2 (ja) * | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2957226C (en) * | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| EP3676268A1 (en) * | 2017-10-20 | 2020-07-08 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificityfor the bromodomain of brd4 |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| BR122022012697B1 (pt) * | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230192644A1 (en) * | 2020-05-21 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Piperidine-2,6-diones as small molecule degraders of helios and methods of use |
-
2019
- 2019-12-03 CN CN201980079725.5A patent/CN113490495B/zh active Active
- 2019-12-03 CA CA3119526A patent/CA3119526A1/en active Pending
- 2019-12-03 JP JP2021531100A patent/JP7709378B2/ja active Active
- 2019-12-03 WO PCT/US2019/064169 patent/WO2020117759A1/en not_active Ceased
- 2019-12-03 US US17/298,823 patent/US12227488B2/en active Active
- 2019-12-03 AU AU2019391016A patent/AU2019391016B2/en active Active
- 2019-12-03 KR KR1020217013263A patent/KR102972506B1/ko active Active
- 2019-12-03 EP EP19891781.7A patent/EP3890736A4/en active Pending
-
2025
- 2025-01-07 US US19/012,206 patent/US20250388562A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551185A5 (enExample) | ||
| JP2023529354A5 (enExample) | ||
| JP2024504932A5 (enExample) | ||
| JP2021532162A5 (enExample) | ||
| JP2021527126A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| JP2021533135A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2021523225A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2006505543A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2018519302A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| JP2011037841A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2005534669A5 (enExample) | ||
| JP2008503515A5 (enExample) | ||
| CA2681972A1 (en) | Substituted dibenzoic acid derivatives and use thereof | |
| JP2019527724A5 (enExample) | ||
| JPWO2023195529A5 (enExample) | ||
| JP2023504542A5 (enExample) | ||
| JP2004523478A5 (enExample) | ||
| CA2626451A1 (en) | Cyclopropylacetic acid derivatives and use thereof |